Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
news
2022-06-03 00:00:00

WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.Â (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 24,000 restricted stock units of Arcutis' common stock as well as options to purchase an aggregate of 64,900 shares of Arcutis' common stock to seven newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc.
